Officers and Directors

Madi Madiyalakan, Ph.D

Chief Executive Officer, Director

Dr. Madiyalakan is the CEO of the Corporation and has served in this capacity since August 2006.  Prior to joining the Corporation, he was one of the founders of SonoLight Pharmaceuticals Corp. (served as its CEO and Director), CanBiocin Inc. (served as President, CEO and Director) and AltaRex Corp. (served as Vice-President, Planning and Chief Scientific Officer).  Between 1987 and 1995 Dr. Madiyalakan served in various senior positions at Biomira Inc.  Dr. Madiyalakan was previously Executive Vice-President, Research and Development of the Corporation.  Dr. Madiyalakan holds a Masters (Chemistry) and Ph.D. (Biochemistry) and a Certificate in Management Development.  In addition, he has over 40 years of academic and industrial research experience on an international basis.  He has published extensively and been an inventor of a number of patents

Lorne Meikle, B.A.

Director (Chairman)

Mr. Meikle is currently the President and Chief Executive Officer of Management Dynamics Ltd., a retired director with Life Sciences Ontario (LSO), where he was founding President in 2010, and the former President & CEO of BCY LifeSciences Inc. (TSXV: BCY). Mr. Meikle was born and raised in Edmonton and is an economics graduate from the University of Manitoba. He has more than 40 years of senior management, marketing and sales management, and director experience in the health care industry. He was a member of the senior management groups at Glaxo Canada, Smith Kline and French, Ortho-McNeil and directed the International marketing program at Connaught Laboratories, now Sanofi Pasteur. In recent years, he was President of TBI, leading the change in the organization to Life Sciences Ontario; Vice President, Immunovaccine Technologies Inc.; President and Chief Executive Officer of Seragen Biopharmaceuticals Ltd., the Canadian affiliate of Seragen Inc., now part of Ligand, Inc; CEO of GeneSense Technologies Inc., merged into Lorus Therapeutics now Aptose Biosciences Inc.; and chaired the steering committee for BIO 2002 in Toronto. Additionally, he was the President, Chief Executive Officer, Founder and a director of BioCatalyst Yorkton Inc., a venture management company that specialized in the formation of, and management of early-stage healthcare companies.

J. Mark Lievonen, C.M., FCPA, FCA, BBA, MBA, LLD


Mr. Lievonen has over 30 years’ experience in the biopharmaceutical industry.  From 1999 to 2016, Mr. Lievonen was the President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi, a global pharmaceutical company.  He is a Director of Oncolytics Biotech Inc., Acerus Pharmaceuticals Corporation, Biome Grow Inc. and the Gairdner Foundation.  Mr. Lievonen has served on a number of industry and not-for-profit boards including as the Chair of R&D (now Innovative Medicines Canada), BIOTECanada, the Markham Stouffville Hospital Foundation, and the Ontario Genomics Institute, Vice-Chair of the Ontario Institute for Cancer Research, as a Director of the Public Policy Forum and as a Governor of York University. Mr. Lievonen was appointed to the Order of Canada in 2015, named a Chevalier de l’Ordre National de Mérite by the government of France in 2007, and was inducted into the Canadian Healthcare Marketing Hall of Fame in 2013. Mr. Lievonen holds a BBA and a MBA from the Schulich School of Business and a Honorary Doctor of Laws from York University.  He was elected as a Fellow of the Institute of Chartered Accountants of Ontario in 2007.

Shawn Lu, CIM, MFin


Mr. Lu is currently the Chief Financial Officer of Hepalink USA Inc. and has served in this capacity since 2014.  From 2013 to 2014, Mr. Lu was employed as the Area Manager for BMO Bank of Montreal in the central Greater Toronto area.  From 2005 to 2013, Mr. Lu worked with the TD Bank as a Residential Mortgage Manager in North York, Toronto.  From 2001 to 2005, Mr. Lu worked as a senior financial advisor for TD Bank in Toronto.  From 1999 to 2000, Mr. Lu was employed with ShenZhen Hepalink Biopharmaceutical Co., Ltd as the CFO and VP of Corporate Finance.  From 1998 to 1999, Mr. Lu was employed as the VP of Investment and Corporate Finance with ShenZhen FuTianXin Investment Co., Ltd.  From 1992 to 1998, Mr. Lu worked as the General Manager, Corporate finance department, and Manager, Investment and Finance department for China Merchant Shekou Port Co. Ltd. (a ShenZhen Stock Exchange listed company).  Mr. Lu has extensive experience in the areas of corporate finance, capital markets and investment financing.  Mr. Lu has a Canadian Investment Manager (CIM, Canada) designation and also a Master of Finance Management from Queens University, School of Business, Kingston, Ontario.  Mr. Lu also holds a Certified Accountant and Certified Corporate Economist designation in China and has a Master of Corporate Economics and Business Administration from ZhongNan University, Wuhan, China.

W. John Meekison, CPA, CMA, P. Log, CIM, B.A.


Mr. Meekison is a career Chief Financial Officer and investment banker.   He has spent the last fifteen years serving in a variety of executive management and CFO roles with both private and public companies, most currently as the CFO of Exro Technologies Inc. and Sojourn Exploration Inc., both publicly traded companies.  Prior to that, Mr. Meekison spent fifteen years in corporate finance with a focus on raising equity capital for North American technology companies, including nine years at Haywood Securities Inc.

Norma Beauchamp, ICD.D


Norma Beauchamp is a director of Aurora Cannabis Inc. and is serving as Chair of the Nominating and Corporate Governance Committee. She is also a director of Acerus Pharmaceuticals Corporation, Chair of their Corporate Governance and Nominating committee and a member of their Audit committee. Formerly, Ms. Beauchamp was a director, Chair of the Corporate Governance and Compensation committees and a member of the Audit Committee of MedReleaf, and Chief Executive Officer of Cystic Fibrosis Canada. Ms. Beauchamp brings over three decades of experience in the corporate and non-profit sectors to her role having held senior leadership positions in Canada and Germany, including executive positions at Bayer and Sanofi. Ms. Beauchamp has served on the Boards of St. Joseph’s Health Centre Foundation, Providence Healthcare Foundation and the Breast Cancer Society of Canada. Throughout her career, she has been a patient advocate, working with patient and healthcare organizations to enhance access to care. Ms. Beauchamp has completed the University of Toronto’s Rotman School of Management Directors Education Program (ICD.D) and holds a Bachelor of Business Administration in Marketing from Bishop’s University.

Pierre Vermette, C.A.

Chief Financial Officer

Pierre Vermette brings to Quest PharmaTech Inc. experience in the areas of securities regulation, corporate governance and financial reporting. Prior to his employment with Quest he was employed for more than 11 years with the Alberta Securities Commission as a Securities Analyst, where he worked in Continuous Disclosure and Corporate Finance. Prior to that, he was employed as a Staff Accountant with MacKay & Partners, Chartered Accountants and also with Ernst & Young LLP.